Omnicell Inc (OQ:OMCL)
Business Focus: Medical Software & Technology Services
| Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 4220 NORTH FREEWAY FORT WORTH TX 76137 |
| Tel: | N/A |
| Website: | https://www.omnicell.com |
| IR: | See website |
| Key People | ||
| Randall A. Lipps Chairman of the Board, President, Chief Executive Officer | Nchacha E. Etta Chief Financial Officer, Executive Vice President | Joseph B. Spears Senior Vice President, Chief Accounting Officer, Corporate Controller |
| Corey J. Manley Senior Vice President, Chief Legal Officer | Brian H. Nutt Chief Accounting Officer, Vice President | |
| Business Overview |
| Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company's XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Omnicell Inc revenues decreased 11% to $1.15B. Net loss totaled $20.4M vs. income of $5.6M. Revenues reflect Connected devices, software licenses, and other segment decrease of 25% to $623.6M, United States segment decrease of 13% to $1.01B. Net loss reflects Impairment of Fixed Assets increase of 6% to $10M (expense), Restructuring Charges & Provisions increase of 6% to $3.8M (expense). |
| Employees: | 3,650 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,385M as of Dec 31, 2023 |
| Annual revenue (TTM): | $1,147M as of Dec 31, 2023 |
| EBITDA (TTM): | $68.04M as of Dec 31, 2023 |
| Net annual income (TTM): | -$20.37M as of Dec 31, 2023 |
| Free cash flow (TTM): | $126.08M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $79.17M as of Dec 31, 2023 |
| Shares outstanding: | 45,923,492 as of Mar 28, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.